Journal of Clinical Oncology
Articles in this Issue
Omission of sentinel node biopsy in early invasive breast cancer: Does age matter?
e12587 Background: National guidelines have supported omission of sentinel lymph node biopsy (SLNB) in patients >70 years with ER+ early invasive breas...
Efficacy and safety of less frequent dosing with elranatamab (ELRA) in patients with relapsed or refractory multiple myeloma (RRMM): A US subgroup analysis from MagnetisMM-3.
7549 Background: The ongoing phase 2 MagnetisMM-3 (NCT04649359) study demonstrated the efficacy and safety of ELRA in patients (pts) with RRMM and no prio...
Clinician perspectives on digital and computational pathology in oncology: Opportunities and challenges.
e15172 Background: Digital and computation pathology (DCP) is a rapidly emerging testing technology seeking to address both workflow constraints in the pa...
Effect of BXQ-350, a novel sphingolipid metabolism modulator, on neuronal environments through modulation of gene pathways.
e24058 Background: Chemotherapeutic Induced Neuropathy (CIPN) remains an obstacle for the successful completion of chemotherapeutic courses. Patients have...
Survival determinants in nodular sclerosis Hodgkin's lymphoma.
e22001 Background: Nodular sclerosis Hodgkin lymphoma (NSHL) is the most common subtype of classical Hodgkin lymphoma, with distinct histological and clin...
Early on-treatment (on-Rx) tumor volume reduction (TVR) to predict response to the KEYNOTE-522 (KN-522) regimen in early stage triple negative breast cancer (TNBC).
592 Background: Monitoring clinical response by breast ultrasound (US) during neoadjuvant therapy is considered standard of care. We previously demonstrat...
Longitudinal change in cardiac function after doxorubicin and dexrazoxane: A report from COG ALTE11C2.
10010 Background: Dexrazoxane (DRZ) has been associated with reduced adverse left ventricular (LV) remodeling shortly after doxorubicin (DOX) treatment (&...
Optimizing therapeutic strategies for metastatic triple-negative breast cancer with homologous recombination deficiency: A Bayesian network meta-analysis.
e13142 Background: Homologous recombination deficiency (HRD) is a key molecular feature in a subset of triple-negative breast cancer (TNBC). The optimal t...
Adverse events and tolerability of immune checkpoint inhibitors (ICI) for the treatment of early stage of breast cancer (BC): A systematic review and meta analysis.
e14621 Background: Programmed cell death-ligand 1 (PD-L1) is an immune checkpoint protein that can downregulate the antitu...
Screening of TROP2, Nectin-4, and HER2 in osteosarcomas: In pursuit of a target.
e23511 Background: Osteosarcoma (OS), the most common malignant bone tumor, primarily affects adolescents and young adults and is associated with poor out...
QUINTESSENTIAL: A multicenter phase 2 study evaluating the efficacy and safety of arlocabtagene autoleucel (arlo-cel) in triple- and quad-class exposed patients with relapsed or refractory multiple myeloma (RRMM).
TPS7563 Background: There are limited treatment options for patients (pts) with RRMM who are triple-class exposed (TCEx: immunomodulatory drugs [IMiD], an...
Clinical outcomes for obese patients with early-onset breast cancer: An analysis of the National Inpatient Sample.
e23356 Background: Despite recent global decreases in overall cancer incidence, the incidence of early-onset breast cancer (EOBC) is steadily increasing g...
Radiomic signatures as predictors of pathological response to neoadjuvant chemoimmunotherapy in surgically resected NSCLC.
8080 Background: Historically, pathological complete response (pCR), a potential early predictor of survival, was achieved by a small fraction of patients...
Breast cancer detection using a realtime breath analyzer: A pilot study.
e13040 Background: Despite advances in mammography, limitations persist related to accuracy among challenging cases (e.g. dense breast tissue) and screeni...
The value of integrating urology and oncology real-world data for understanding prostate cancer management.
e17011 Background: Real-world data (RWD) is essential for understanding current management and outcomes of patients with prostate cancer. Most observation...
Clinical utility of a tumor-naïve circulating tumor DNA (ctDNA) test to predict outcomes in patients with advanced testicular germ cell tumors.
5032 Background: Serum tumor markers (STM) used in the management of Testicular Germ Cell Tumors (TGCT) lack sufficient specificity and are not altered in...
Telehealth utilization in neuro-oncology: A single institution experience.
e13893 Background: For individuals with CNS tumors who have experience difficulties with in-person (IP) evaluations due to disease-related neurologic disa...
Real-world incidence of thrombosis and cardiovascular adverse events associated with immune checkpoint inhibitors in a Hispanic population: A retrospective single-center study.
e14622 Background: Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 have revolutionized cancer treatment. However, emerging evidence...
A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody, with or without chemotherapy in subjects with advanced pancreatic cancer.
TPS4231 Background: Traditional immune checkpoint inhibitors have shown limited benefit in pancreatic ductal adenocarcinoma (PDAC) owing to non-redundant...
Epidemiology, treatment patterns, and survival outcomes of spermatocytic seminoma: A National Cancer Database analysis.
5027 Background: Spermatocytic seminoma (SS) is a rare germ cell tumor, representing 2-5% of seminomas. Unlike classical seminomas, SS primarily affects o...
Sequential hepatic artery infusion chemotherapy and transarterial chemoembolization combined with anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors and immune checkpoint inhibitors (quadruple therapy) as first-line therapy for advanced hepatocellular carcinoma: A single-center retrospective cohort study.
e16180 Background: Sequential hepatic artery infusion chemotherapy (HAIC) and transarterial chemoembolization (TACE) may synergistically increase the drug...
Gamma secretase inhibitors and desmoid fibromatosis: Lessons from a real world, comprehensive genomic study of desmoids and <i>CTNNB1</i> / <i>APC</i> mutated soft tissue tumors.
11547 Background: Recently, first-in-class FDA approval was granted in the U.S. for use of the gamma secretase inhibitor (GSI), nirogacestat, for adults w...
Enhancing soft tissue sarcoma surveillance: The role of ctDNA testing in early detection and monitoring beyond traditional imaging.
11577 Background: Soft tissue sarcoma (STS), particularly large (>5 cm), intermediate to high grade, and aggressive subtypes, is associated with high r...
Impact of protein energy malnutrition on hospitalized patients with breast cancer: A United States population-based cohort study.
11067 Background: Advances in chemotherapeutics and surgical options have improved survival in patients with breast cancer. With prolonged survival, these...
Proportion of positive lymph nodes in relation to survival of patients with epithelial ovarian cancer in advanced clinical stages in the National Medical Center "20 de Noviembre.
e17601 Background: Ovarian cancer is a public health problem. The fourth most frequent gynecological neoplasm and the second with the highest mortality, w...